AI-Driven Industry Solutions

Industry Challenges

Pharmaceutical manufacturing faces intensifying pressure to improve efficiency, reduce environmental impact, and accelerate time-to-market:

• Complex molecule synthesis: Modern drug candidates feature multiple stereocenters, complex ring systems, and sensitive functional groups that challenge traditional synthetic approaches.
• Regulatory stringency: Increasingly demanding purity specifications, impurity profiling requirements, and environmental compliance standards constrain process design flexibility.
• Cost pressure: Generic competition, pricing scrutiny, and manufacturing consolidation demand continuous cost reduction without compromising quality.
• Sustainability mandates: Corporate carbon neutrality commitments and green chemistry initiatives require elimination of hazardous reagents and reduction of solvent and energy consumption.
• Supply chain vulnerability: Reliance on specialized chemical intermediates and exotic reagents creates single-source risks and geographic concentration.

Biocatalysis offers solutions to these challenges, but pharmaceutical deployment requires enzymes engineered for process conditions, regulatory compliance, and manufacturing economics—not merely biological activity.

AI-Enabled Solution Strategy

Our pharmaceutical solutions integrate computational enzyme engineering with process development expertise:

Key Capabilities

• Chiral Synthesis: Enantioselective biocatalysis for single-enantiomer drug intermediates
• Late-Stage Functionalization: Direct modification of advanced intermediates without protecting group manipulation
• Hazardous Reagent Replacement: Elimination of pyrophoric, toxic, or corrosive reagents from synthetic routes
• Route Shortening: Biocatalytic steps that combine multiple chemical transformations
• Impurity Control: Enzymatic selectivity that reduces byproduct formation and simplifies purification

Our Industry Solutions

Typical Workflow

1. Target Analysis: Synthetic route, substrate structures, and manufacturing constraints are reviewed. Biocatalytic opportunities are identified and ranked by technical feasibility and economic impact.

2. Enzyme Sourcing: Computational mining and focused screening identify candidate enzymes with remotely related activities. AI models predict compatibility with target substrates and process conditions.

3. Engineering and Optimization: Variants are designed for improved activity, selectivity, and stability under manufacturing conditions. Iterative cycles converge on process-ready biocatalysts.

4. Process Development: Reaction conditions, cofactor recycling, and downstream integration are optimized for volumetric productivity and cost efficiency. Scale-up parameters are established.

5. Validation and Transfer: Comprehensive characterization supports regulatory documentation. Technology transfer packages enable manufacturing implementation.

Use Cases

Why Creative Enzymes

FAQs

• Q: What is the typical timeline for route development?

  A: 12–18 months from target analysis to validated biocatalytic process for moderate-complexity transformations. Expedited programs with compressed milestones are available.

• Q: Can you work with proprietary structures?

  A: Yes. All projects operate under confidentiality agreements. Proprietary information is protected, and client IP positions are respected.

• Q: Do you support regulatory filings?

  A: Yes. We provide characterization data, process descriptions, and quality documentation suitable for regulatory submission. Direct agency interaction is coordinated with client regulatory affairs.

• Q: What manufacturing scales do you support?

  A: Process development through pilot scale (kg to tens of kg). Technology transfer packages support manufacturing scale-up to commercial quantities.

• Q: Can biocatalysis integrate with existing chemical routes?

  A: Yes. Biocatalytic steps are designed for compatibility with existing infrastructure and can replace single steps or entire route segments.

• Q: How do you handle enzyme supply for commercial manufacturing?

  A: Optimized expression strains and manufacturing protocols are provided for client or contract manufacturer production. Commercial supply arrangements can be established.